Intent to Sole Source-Adenovirus (Ad-PON1-G3C9-1F11)

The US Army Medical Research Acquisition Activity (USAMRAA) intends to solicit and award a sole source firm-fixed price contract, under Federal Acquisition Regulation (FAR) Part 13, Simplified Acquisition Procedures (SAP) under the sole source authority of FAR Subpart 13-106-1(b) for a specific adenovirus, Ad-PON1-G3C9-1F11. The solicitation is, W81XWH-14-T-0091. NAICs 541711. Estimated value is $65,000.00 for a base year ($21,000.00) and two option years.

Welgen Inc synthesized the genetically unique adenovirus Ad-PON1-G3C9-1F11 under a previous contract, W81XWH-12-P-0333, and perfected the large-scale amplification and purification process required for the product to meet the Government's testing standards. Research experiments using this virus is currently on-going at USAMRICD. Thus, it is not in the Government's best interest to compete this requirement.

This is not a request for competitive proposals/quotations and is not to be construed as a commitment by the Government. However, all responsible sources may submit a capability statement, proposal or quotation, not later than (NLT) 13 FEB 2014 at 1100hrs, which will be considered by the Agency. No cost shall be incurred by the Government for submittals in response to this notice. Any questions maybe emailed to Jacklyn McGurk, email: sjacklyn.r.mcgurk.civ@mail.mil.

A determination by the Government not to compete this requirement based on the responses to this notice is solely within the discretion of the Government.